Zenas Biopharma posts corporate presentation on autoimmune disease drug pipeline, led by obexelimab

Zenas BioPharma

Zenas BioPharma

ZBIO

0.00
  • Zenas Biopharma outlined plans to transition to a commercial-stage autoimmune company, citing cash runway into 2029.
  • Obexelimab IgG4-RD BLA submitted to the FDA; MAA filing to the EMA planned in H2 2026.
  • INDIGO Phase 3 IgG4-RD met the primary endpoint; flare risk reduced 56% vs placebo, HR 0.41; 73% flare-free at week 52.
  • Pipeline focus spans obexelimab, orelabrutinib, ZB021; clinical catalysts include SunStone Phase 2 SLE topline in Q4 2026.
  • Zenas targets potential approvals for three franchise molecules across five I&I indications by 2031; markets estimated at more than $50 billion.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zenas Biopharma Inc. published the original content used to generate this news brief on June 02, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.